Country Presentations of FNCA FY2007 Workshop on Radiation Oncology

Similar documents
PILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia)

RECTAL CANCER CLINICAL CASE PRESENTATION

Enterprise Interest None

Proposed All Wales Vulval Cancer Guidelines. Dr Amanda Tristram

Chapter 5 Stage III and IVa disease

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.

Adjuvant Therapies in Endometrial Cancer. Emma Hudson

receive adjuvant chemotherapy

Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99

Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases

North of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix

Isolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix

Management of Cervical Cancer in Resource Limited Settings

Adjuvant Chemotherapy for Rectal Cancer: Are we making progress?

Oral cavity cancer Post-operative treatment

Radiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department

Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice?

CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER

Nasopharynx. 1. Introduction. 1.1 General Information and Aetiology

Nasopharyngeal Cancer/Multimodality Treatment

ARROCase: Locally Advanced Endometrial Cancer

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008

Chemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002

Locally advanced disease & challenges in management

Treatment of oligometastatic NSCLC

PORTEC-4. Patient seqnr. Age at inclusion (years) Hospital:

Staging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion

Nasopharyngeal Cancer:Role of Chemotherapy

Treatment outcomes and prognostic factors of gallbladder cancer patients after postoperative radiation therapy

Doppler ultrasound of the abdomen and pelvis, and color Doppler

COX-2 inhibitor and irradiation. Saitama Cancer Center Kunihiko Kobayashi MD, PhD

Chun-Chieh Wang, MD and Feng-Yuan Liu, MD/ Prof. Chyong-Huey Lai, MD

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

Radiation Oncology MOC Study Guide

GCIG Rare Tumour Brainstorming Day

Radiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2

Radiation therapy with chemotherapy for patients with cervical cancer and supraclavicular lymph node involvement

3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX

Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus

Combining chemotherapy and radiotherapy of the chest

Enrollment Form: Pancreas

Trimodality Therapy for Muscle Invasive Bladder Cancer

3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014

The Evolution of RT Techniques for Gynaecological Cancers in a developing country context

Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer

Oral Cavity. 1. Introduction. 1.1 General Information and Aetiology. 1.2 Diagnosis and Treatment

Hypopharynx. 1. Introduction. 1.1 General Information and Aetiology

Cervical Cancer 3/25/2019. Abnormal vaginal bleeding

RESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods

GUIDELINES ON RENAL CELL CANCER

Mini J.Elnaggar M.D. Radiation Oncology Ochsner Medical Center 9/23/2016. Background

San Antonio Breast Cancer Symposium 2010 Highlights Radiotherapy

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER

The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology

New Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%

Case Scenario 1. History

- RET/PTC rearrangement: 20% papillary thyroid cancer - RET: medullary thyroid cancer

Prognostic value of pretreatment and recovery duration of cranial nerve palsy in nasopharyngeal carcinoma

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET

Management of Neck Metastasis from Unknown Primary

Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.

State of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center

pros and cons

Proton or Photon RT for Retroperitoneal Sarcomas

Effective local and systemic therapy is necessary for the cure of Ewing tumor Most chemotherapy regimens are a combination of cyclophosphamide,

Radiotherapy Physics and Equipment

Johannes C. Athanasios Dimopoulos

Vaginal intraepithelial neoplasia

Melanoma Quality Reporting

Patterns of Care in Patients with Cervical Cancer:

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

Maria João Cardoso, MD, PhD

Guideline for the Management of Vulval Cancer

Algorithms for management of Cervical cancer

Radiation Therapy for Thyroid Cancer. When is Radiation Therapy indicated in Thyroid Cancer of Follicular or Parafollicular Cell Origin?

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Oncology 101. Marianne Davies, RN, APRN Yale Cancer Center September 2006

Radiotherapy for Rectal Cancer. Kevin Palumbo Adelaide Radiotherapy Centre

Thoracic Recurrences. Soft tissue recurrence

PET/CT in breast cancer staging

Cervical cancer is a disease in which malignant (cancer) cells form in the tissues of the cervix.

Staging and Treatment Update for Gynecologic Malignancies

Oncology General Principles L A U R I E S I M A R D B R E A S T S U R G I C A L O N C O L O G Y F E L L O W D E C E M B E R

Index. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.

Nasopharynx Cancer. 1 Feb Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar)

Interstitial Brachytherapy. Low dose rate brachytherapy. Brachytherapy alone cures some cervical cancer. Learning Objectives

Clinical Discussion. Dr Pankaj Chaturvedi. Professor and Surgeon Tata Memorial Hospital

Heterogeneity of N2 disease

Supplementary Appendix

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

8/2/2012. Mapping Anatomically Sensitive Bone Marrow Regions. Hematopoietic Functions of Bone Marrow. Radiosensitivity of Bone Marrow

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Abscopal Effect of Radiation on Toruliform Para-aortic Lymph Node Metastases of Advanced Uterine Cervical Carcinoma A Case Report

GCIG Cervix Committee: Chicago, USA May 30th Satoru Sagae (JGOG) Bradley Monk (GOG)

Clinical Management Guideline for Small Cell Lung Cancer

Head and Neck Reirradiation: Perils and Practice

ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)

The Role of Radiation Therapy in the Treatment of Brain Metastases. Matthew Cavey, M.D.

Transcription:

Country Presentations of FNCA FY2007 Workshop on Radiation Oncology Annex 3 Country presentations on CERVIX-III -China: Total Patients: 18, 8 alive: 1 with metastasis lung, another one metastasis to liver; 10 patients death; The treatments of 2 patients with metastasis are being performed. -Indonesia: Total Patients: 5; 2 Alive no evidence of disease; No late effect appear; 3 patients death: 2 due to disease and 1 not related to disease; OTT: 44 days. -Japan: Total patients: 32, CT/MRI was done for all cases; OTT : 49 days; Chemo 63 % received 4 times; Acute toxicity appeared as leucopenia, neutropenia but radiotherapy were not discontinued because of grade 1-2 toxicities. Site of failure to PALN 10 patients (30 %). -Korea: Patients: 10; Local control 87.5 % and DSS 75 %, Complication: all in grade 1-2; 1 patients had metastasis to the lung (soliter) treated by Cyberknife machine. PET scan was used as tool for follow-up setting. -Malaysia: Total patients: 14; OTT: 31-51 Days; 31 Days seem to be a little shorter (only from UMMC) than usual. Toxicity: only grade 1-2, no evidence of grade 3-4. -The Philippines: Patients: 12; Stage IIB: 9, Stage IIIB: 3; OTT 37-112 days. Toxicity; grade 1-2, while no grade 3-4 both acute or late. Response rate: 100 %; Disease status: Local failure 2, Distant metastasis 3, Progression 6, 2 patients received additional treatment. -Thailand: Total patients: 19; OTT 41-61 days; Acute Hematologic Toxicity grade 3-4 2 patients and acute non-hematologic grade 3-4 2 patients, other in grade 1-2. 10/19 (52.6 %) were progression free of disease. All late toxicity in grade 1-2. Death: 8 patients, 4 in 9 patients (44%) causes by distant metastasis. -Vietnam: Patients: 9; Local failure 2; Distant metastasis 3, Acute toxicity grade 3: 2 patients, neutrophenia grade 4: 1 patient. Late effect grade 4: 2 patients. (Total: 10 patients. 1 patient died 2006)

Annex 4 Country presentations on Cervix-IV Cervix-IV -Indonesia: Dr. Supriana reported clinical results of the CHE-RAD and Extended-Field Radiotherapy for Locally Advanced Cervical Cancer (CERVIX-IV) with 3 patients from Indonesia, stage IIIB, PALN negative. One patient has inguinal lymphatic nodes. The problem is poor people, long waiting list and quality of CT scan. -Korea: Dr. Cho, reported clinical results of 5 patients, stage IIIB and used PET and MRI for detecting PALN. He has used 3-D conformal planning treatment, and not used 4-Field box technique. -The Philippines: Dr. Reyes reported clinical results of 3 patients, stage IIB with one patient has PALN (1 cm). They used large fields with Cobalt, and 2 fields AP-PA common field borders at L4-L5 with Co-60. -China: Dr. Kato, Japan, reported the data of 3 patients sent from China. They treated EXT pelvic 50Gy + PALN 40-60 Gy, which may be higher than protocol (prophylactic 36 Gy).

Annex 5 Country presentations on NPC-I NPC-I -China: Number of patients: 25,Median age: 54 years, Stage III: 16; IVA: 5; IVB: 4, All patients with histology WHO type 2, 0/25 (0%) patients needed interruption of RT, CR was 92%, Most people were tolerable to the regimen, First sites of failure: Locoregional: 3; Distant metastasis: 3; Both: 2, PET CT imaging has advantages in distinguishing the tumor relapse from necrosis in follow-up of post RT. -Indonesia: Number of patients: 3, Median age: 34 years, All patients with histology WHO type 3 and stage IVB, 2/3 patients were interrupted, Duration of interruption: median 24 d (10-38 d), Cause: 2 mucositis, Patient did not continue to adjuvant chemotherapy, possibly reason: the patient feels better even though the treatment is not complete, so they think it is not necessary to continue the treatment. -Korea: There is no patient including this study. Only presentation about the pilot study: Combined RT + Chemotherapy and give Cyberknife boost to Nasopharynx. -Malaysia: Number of patients: 26, Stage III: 16; IVA: 7; IVB: 3,Histology WHO type 2: 11; type 3: 15, 4/26 (15 %) patients needed interruption in the treatment (1-17 d), Completed 3 cycle Concurrent chemotherapy: 13/26 patients, Completed 3 cycle Adjuvant chemotherapy: 19/26 patients, Local failure: None; Distant metastasis: 3/25 patients; Progression 3/25 patients, Alive: 19/26 (73%) patients. -Thailand: Number of patients: 5, Median age: 45 years, T2bN2Mo: 2; T3N2Mo: 1; T4N2Mo: 1; T4N3Mo: 1, Response of treatment: CR 5/5 patients, Loco-regional failure: None; Distant metastasis: 1/5 patients, Progression free survival: 4/5 patients. Overall survival: 4/5 patients. Acute toxicity (Concurrent): Non-Hematology: most of them grade I & II, but 3 patients suffer from mucositis grade 3 and 2 patients suffer from fatigue grade 3. Hematology: most of them grade I, Acute toxicity (Adjuvant ): WBC grade 3-4: 3 patients; ANC grade 3-4: 4 patients. -Vietnam: Number of patients: 51, Median age: 44 years (range 16-64), ineligible cases 20, 15 loss information; try finding, Stage III: 23; IVA: 1; IVB: 27, All patients with Histology WHO type: 3, 22/51 patients needed interruption of RT, Duration: Median 12 d (1-6weeks), With the reason: 21 acute non-hematology toxicity; 5 acute hematology toxicity; 12 machine breakdown. CR: 23/29 (73 %), First site of failure: 36; Locoregional: 2; Distant metastasis: 3 ( 2 bone metastasis and 1 brain metastasis ), Both: 1, and PS: 1 after complete treatment, Total 51 patients-> now: alive 29 patients, (died with diseases 7, loss information:15).

-The Philippines: Number of patients: 3, Stage III: 2; Stage IV: 1, Response to tumor: 1 no recurrence; 1 residual; 1 no changed, Toxicities: gradeⅠxerostomia.

Annex 6 Country presentations on NPC-II NPC-II -Indonesia reported 6 patients with stage III 4 patients and stage IVA 2 patients. All patients have been examined with chest-x-ray nasopharyngoscope, CT scan of head & neck, bone scan and ultrasonography of abdomen. For two patients, radiation was interrupted because of toxicity. Chemotherapy was given for 6 cycles. The toxicity is only grade I and grade II toxicity. Up to November 2007, there has been two death, one from lung metastases and one death unrelated to disease. -Malaysia reported 5 patients with stage III and IV. Chemotherapy was give 1 cycle for 1 patient, 2 cycle for 1 patient, 3 cycles for 1 patients, 4 cycles for 1 patient and 5 cycles for 1 patient. Majority of patients have Grade I, normal tissue side effects 40% (2/5), developed distant metastases. None developed local recurrence. -Thailand reported only one patient. Chemotherapy was give up to 8 cycles outside center. Chemotherapy and radiation therapy was interrupted because of intercurrent disease.